ANDA 209013, held by Somerset Theraps LLC. Doxazosin Mesylate.
As of Nov 16, 2026, ANDA 209013 (Doxazosin Mesylate), held by Somerset Theraps LLC, was first approved by FDA on Apr 17, 2018, with 1 approved supplement and 0 published complete response letters.
Doxazosin tablets are an alpha 1 adrenergic antagonist indicated for: Signs and symptoms of Benign Prostatic Hyperplasia (BPH) Treatment of Hypertension 1.1 Benign Prostatic Hyperplasia (BPH) Doxazosin tablets are indicated for the treatment of the signs and symptoms of BPH. 1.2 Hypertension Doxazosin tablets are indicated for the treatment of hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes, including this drug.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Apr 17, 2018 | Original application | Approved | None posted |
| Doxazosin MesylateEQ 1MG BASE · tablet;oral | Doxazosin Mesylate | Rx |
| Doxazosin MesylateEQ 2MG BASE · tablet;oral | Doxazosin Mesylate | Rx |
| Doxazosin MesylateEQ 4MG BASE · tablet;oral | Doxazosin Mesylate | Rx |
| Doxazosin MesylateEQ 8MG BASE · tablet;oral | Doxazosin Mesylate | Rx |
| Jun 13, 2024 | Supplement 2Labeling · Standard review | Approved | None posted |
| Apr 17, 2018 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters